Canadian researchers are harnessing the power of 'liquid biopsies' to detect traces of tumours lingering after cancer treatment, offering a promising new approach to cancer monitoring. This innovative technique, which utilizes simple blood tests to identify tumour DNA, has the potential to revolutionize how clinicians monitor disease recurrence. While access to liquid biopsies is currently limited to clinical trials or expensive private clinics, there is growing optimism that this could change. Dr. Ramy Saleh, a cancer researcher and medical oncologist, believes that this approach could "revolutionize" cancer care, enabling early detection and potentially offering patients a better chance at curative treatment. A Toronto-based team is embarking on a massive research project to explore the use of liquid biopsies in routine patient care, aiming to enhance cancer survivors' protection against disease recurrence while minimizing the need for costly and invasive treatments. The project, led by scientists from the University Health Network (UHN), involves offering liquid biopsies to over 7,000 patients who have undergone traditional cancer treatments. The goal is to detect circulating tumour DNA, which could indicate the possibility of cancer recurrence, and to link patients with clinical trials offering experimental immunotherapy, new drugs, or GLP-1s for further treatment. However, the technology is still in its early stages, with ongoing research to understand its effectiveness and potential applications. Dr. Lillian Siu, the study lead, emphasizes the importance of early detection and the potential for liquid biopsies to guide follow-up care. The project, named SHERLOCK, aims to detect cancer before it becomes visible on routine exams or scans, offering patients a better chance at successful treatment. Despite the promise, there are ethical considerations and challenges. Dr. Christopher Booth highlights the psychological impact of knowing about potential cancer cells in the body, while also acknowledging the need for further study and the potential for false positives and negatives. The cost of liquid biopsies is another concern, with some tests costing over $2,000, making them unaffordable for many. However, there is hope that projects like UHN's clinical trial will provide evidence of cost-effectiveness and improved quality of life for patients. As the technology advances and becomes more accessible, liquid biopsies could become a routine part of cancer care, offering a non-invasive and potentially life-saving tool for cancer monitoring and treatment.
